Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone

Authors: Min Wei, Qi He, Zhongyin Yang, Zhiwei Wang, Qing Zhang, Bingya Liu, Qinlong Gu, Liping Su, Yingyan Yu, Zhenggang Zhu, Guofeng Zhang

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Progesterone is essential for the proliferation and differentiation of mammary gland epithelium. Studies of breast cancer cells have demonstrated a biphasic progesterone response consisting of an initial proliferative burst followed by sustained growth arrest. However, the transcriptional factors acting with the progesterone receptor (PR) to mediate the effects of progesterone on mammary cell growth and differentiation remain to be determined. Recently, it was demonstrated that signal transducer and activator of transcription 6 (Stat6) is a cell growth suppressor. Similar to progesterone-bound PR, Stat6 acts by inducing the expression of the G1 cyclin-dependent kinase inhibitors p21 and p27. The possible interaction between Stat6 and progesterone pathways in mammary cells was therefore investigated in the present study.

Methods

ChIP and luciferase were assayed to determine whether Stat6 induces p21 and p27 expression by recruitment at the proximal Sp1-binding sites of the gene promoters. Immunoprecipitation and Western blotting were performed to investigate the interaction between Stat6 and PR-B. The cellular DNA content and cell cycle distribution in breast cancer cells were analyzed by FACS.

Results

We found that Stat6 interacts with progesterone-activated PR in T47D cells. Stat6 synergizes with progesterone-bound PR to transactivate the p21 and p27 gene promoters at the proximal Sp1-binding sites. Moreover, Stat6 overexpression and knockdown, respectively, increased or prevented the induction of p21 and p27 gene expression by progesterone. Stat6 knockdown also abolished the inhibitory effects of progesterone on pRB phosphorylation, G1/S cell cycle progression, and cell proliferation. In addition, knockdown of Stat6 expression prevented the induction of breast cell differentiation markers, previously identified as progesterone target genes. Finally, Stat6 gene expression levels increased following progesterone treatment, indicating a positive auto-regulatory loop between PR and Stat6.

Conclusions

Taken together, these data identify Stat6 as a coactivator of PR mediating the growth-inhibitory and differentiation effects of progesterone on breast cancer cells.
Appendix
Available only for authorised users
Literature
1.
Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 2010, 363 (20): 1938-1948. 10.1056/NEJMra1001389.CrossRefPubMed
2.
Schneider MR, Michna H, Nishino Y, el Etreby MF: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol. 1990, 37 (6): 783-787. 10.1016/0960-0760(90)90420-P.CrossRefPubMed
3.
Ismail PM, DeMayo FJ, Amato P, Lydon JP: Progesterone induction of calcitonin expression in the murine mammary gland. J Endocrinol. 2004, 180 (2): 287-295. 10.1677/joe.0.1800287.CrossRefPubMed
4.
Conneely OM, Mulac-Jericevic B, Arnett-Mansfield R: Progesterone signaling in mammary gland development. Ernst Schering Found Symp Proc. 2007, 1: 45-54.PubMed
5.
Conneely OM, Jericevic BM, Lydon JP: Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003, 8 (2): 205-214. 10.1023/A:1025952924864.CrossRefPubMed
6.
Shyamala G, Yang X, Cardiff RD, Dale E: Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci U S A. 2000, 97 (7): 3044-3049. 10.1073/pnas.97.7.3044.CrossRefPubMedPubMedCentral
7.
Ramamoorthy S, Dhananjayan SC, Demayo FJ, Nawaz Z: Isoform-specific degradation of PR-B by E6-AP is critical for normal mammary gland development. Mol Endocrinol. 2010, 24 (11): 2099-2113. 10.1210/me.2010-0116.CrossRefPubMed
8.
9.
Stingl J: Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2011, 2 (2): 85-90. 10.1007/s12672-010-0055-1.CrossRefPubMed
10.
Medina D, Kittrell FS, Tsimelzon A, Fuqua SA: Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice. Ernst Schering Found Symp Proc. 2007, 1: 109-126.PubMed
11.
Botella J, Duranti E, Duc I, Cognet AM, Delansorne R, Paris J: Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol. 1994, 50 (1–2): 41-47.CrossRefPubMed
12.
Schoonen WG, Joosten JW, Kloosterboer HJ: Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J Steroid Biochem Mol Biol. 1995, 55 (3–4): 439-444.CrossRefPubMed
13.
Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL: Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 1988, 48 (18): 5084-5091.PubMed
14.
Chen B, Pan H, Zhu L, Deng Y, Pollard JW: Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase– > AKT– > GSK-3beta– > cyclin D1– > pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol. 2005, 19 (8): 1978-1990. 10.1210/me.2004-0274.CrossRefPubMed
15.
Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL: Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol. 1998, 18 (4): 1812-1825.CrossRefPubMedPubMedCentral
16.
Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997, 11 (11): 1593-1607. 10.1210/mend.11.11.0006.CrossRefPubMed
17.
Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL: Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol. 1997, 11 (1): 54-66. 10.1210/mend.11.1.9869.CrossRefPubMed
18.
Eigeliene N, Harkonen P, Erkkola R: Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues. Cell Cycle. 2008, 7 (1): 71-80. 10.4161/cc.7.1.5102.CrossRefPubMed
19.
Gizard F, Robillard R, Gervois P, Faucompre A, Revillion F, Peyrat JP, Hum WD, Staels B: Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett. 2005, 579 (25): 5535-5541. 10.1016/j.febslet.2005.08.084.CrossRefPubMed
20.
Swarbrick A, Lee CS, Sutherland RL, Musgrove EA: Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol. 2000, 20 (7): 2581-2591. 10.1128/MCB.20.7.2581-2591.2000.CrossRefPubMedPubMedCentral
21.
Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998, 273 (17): 10696-10701. 10.1074/jbc.273.17.10696.CrossRefPubMed
22.
Wang J, Hu Y, Nekvindova J, Ingelman-Sundberg M, Neve EP: IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. Biochem Pharmacol. 2010, 80 (10): 1592-1600. 10.1016/j.bcp.2010.08.005.CrossRefPubMed
23.
Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH: Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev. 2005, 26 (4): 525-582. 10.1210/er.2002-0050.CrossRefPubMed
24.
Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T: Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett. 1997, 411 (1): 1-6. 10.1016/S0014-5793(97)00660-1.CrossRefPubMed
25.
Pang H, Rowan BG, Al-Dhaheri M, Faber LE: Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells. Breast Cancer Res. 2004, 6 (3): R239-R245. 10.1186/bcr780.CrossRefPubMedPubMedCentral
26.
Qu Y, Li JF, Cai Q, Wang YW, Gu QL, Zhu ZG, Liu BY: Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation. J Cancer Res Clin Oncol. 2008, 134 (3): 353-364. 10.1007/s00432-007-0291-0.CrossRefPubMed
27.
Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, et al: PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest. 2005, 115 (11): 3228-3238. 10.1172/JCI22756.CrossRefPubMedPubMedCentral
28.
Wei M, Liu B, Su L, Li J, Zhang J, Yu Y, Yan M, Yang Z, Chen X, Liu J, et al: A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells. Mol Cancer Ther. 2010, 9 (6): 1764-1774. 10.1158/1535-7163.MCT-09-1162.CrossRefPubMed
29.
Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, Topisirovic I, Sonenberg N, Thomas G, Kozma SC: S6K1 plays a critical role in early adipocyte differentiation. Dev Cell. 2010, 18 (5): 763-774. 10.1016/j.devcel.2010.02.018.CrossRefPubMedPubMedCentral
30.
Dubey R, Chhabra R, Saini N: Small interfering RNA against transcription factor STAT6 leads to increased cholesterol synthesis in lung cancer cell lines. PLoS One. 2011, 6 (12): e28509-10.1371/journal.pone.0028509.CrossRefPubMedPubMedCentral
31.
Wei M, Wang ZW, Yao HL, Yang ZY, Zhang Q, Liu BY, Yu YY, Su LP, Zhu ZG, Gu QL: P27(Kip1), regulated by glycogen synthase kinase-3beta, results in HMBA-induced differentiation of human gastric cancer cells. BMC Cancer. 2011, 11: 109-10.1186/1471-2407-11-109.CrossRefPubMedPubMedCentral
32.
Chien WW, Domenech C, Catallo R, Salles G, Ffrench M: S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53. Cell Cycle. 2010, 9 (16): 3286-3296.
33.
Graham ML, Dalquist KE, Horwitz KB: Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analysis of breast cancer cell mixtures and genetic instability of the T47D line. Cancer Res. 1989, 49 (14): 3943-3949.PubMed
34.
Graham ML, Bunn PA, Jewett PB, Gonzalez-Aller C, Horwitz KB: Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines. Cancer Res. 1989, 49 (14): 3934-3942.PubMed
35.
Wei M, Liu B, Gu Q, Su L, Yu Y, Zhu Z: Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). Cell Oncol (Dordr). 2012, 36 (1): 79-93.CrossRef
36.
Liu Z, Wong J, Tsai SY, Tsai MJ, O’Malley BW: Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin. Proc Natl Acad Sci U S A. 2001, 98 (22): 12426-12431. 10.1073/pnas.231474798.CrossRefPubMedPubMedCentral
37.
Rowan BG, Garrison N, Weigel NL, O’Malley BW: 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol. 2000, 20 (23): 8720-8730. 10.1128/MCB.20.23.8720-8730.2000.CrossRefPubMedPubMedCentral
38.
Arpa L, Valledor AF, Lloberas J, Celada A: IL-4 blocks M-CSF-dependent macrophage proliferation by inducing p21Waf1 in a STAT6-dependent way. Eur J Immunol. 2009, 39 (2): 514-526. 10.1002/eji.200838283.CrossRefPubMed
39.
Sumida T, Itahana Y, Hamakawa H, Desprez PY: Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Cancer Res. 2004, 64 (21): 7886-7892. 10.1158/0008-5472.CAN-04-1155.CrossRefPubMed
40.
Tikoo K, Kumar P, Gupta J: Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer. 2009, 9: 107-10.1186/1471-2407-9-107.CrossRefPubMedPubMedCentral
41.
Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, et al: Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res. 2007, 13 (1): 246-252. 10.1158/1078-0432.CCR-06-1947.CrossRefPubMed
42.
Musgrove EA, Lee CS, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol. 1991, 11 (10): 5032-5043.CrossRefPubMedPubMedCentral
43.
Skildum A, Faivre E, Lange CA: Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol. 2005, 19 (2): 327-339. 10.1210/me.2004-0306.CrossRefPubMed
44.
Lu S, Becker KA, Hagen MJ, Yan H, Roberts AL, Mathews LA, Schneider SS, Siegelmann HT, MacBeth KJ, Tirrell SM, et al: Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology. 2008, 149 (10): 4809-4820. 10.1210/en.2008-0035.CrossRefPubMedPubMedCentral
45.
Obr AE, Edwards DP: The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol. 2012, 357 (1-2): 4-17. 10.1016/j.mce.2011.10.030.CrossRefPubMed
46.
Hilton HN, Kalyuga M, Cowley MJ, Alles MC, Lee HJ, Caldon CE, Blazek K, Kaplan W, Musgrove EA, Daly RJ, et al: The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. Mol Endocrinol. 2010, 24 (7): 1380-1392. 10.1210/me.2009-0516.CrossRefPubMed
47.
Lehtonen E, Stefanovic V, Saraga-Babic M: Changes in the expression of intermediate filaments and desmoplakins during development of human notochord. Differentiation. 1995, 59 (1): 43-49. 10.1046/j.1432-0436.1995.5910043.x.CrossRefPubMed
48.
Kester HA, van der Leede BM, van der Saag PT, van der Burg B: Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem. 1997, 272 (26): 16637-16643. 10.1074/jbc.272.26.16637.CrossRefPubMed
49.
Chalbos D, Escot C, Joyeux C, Tissot-Carayon MJ, Pages A, Rochefort H: Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization. J Natl Cancer Inst. 1990, 82 (7): 602-606. 10.1093/jnci/82.7.602.CrossRefPubMed
50.
Chalbos D, Joyeux C, Galtier F, Escot C, Chambon M, Maudelonde T, Rochefort H: Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev Esp Fisiol. 1990, 46 (1): 43-46.PubMed
51.
Wasserman L, Nordenberg J, Beery E, Deutsch AA, Novogrodsky A: Differential effects of sodium butyrate and dimethylsulfoxide on gamma-glutamyl transpeptidase and alkaline phosphatase activities in MCF-7 breast cancer cells. Exp Cell Biol. 1987, 55 (4): 188-193.PubMed
52.
Leo JC, Wang SM, Guo CH, Aw SE, Zhao Y, Li JM, Hui KM, Lin VC: Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int J Cancer. 2005, 117 (4): 561-568. 10.1002/ijc.21186.CrossRefPubMed
53.
Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, O’Malley BW: Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res. 1997, 52: 141-164. discussion 164–145PubMed
54.
Pagliuca A, Gallo P, Lania L: Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J Cell Biochem. 2000, 76 (3): 360-367. 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1.CrossRefPubMed
55.
Xiao H, Hasegawa T, Isobe K: p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem. 2000, 275 (2): 1371-1376. 10.1074/jbc.275.2.1371.CrossRefPubMed
56.
Mikita T, Daniel C, Wu P, Schindler U: Mutational analysis of the STAT6 SH2 domain. J Biol Chem. 1998, 273 (28): 17634-17642. 10.1074/jbc.273.28.17634.CrossRefPubMed
57.
Goenka S, Youn J, Dzurek LM, Schindler U, Yu-Lee LY, Boothby M: Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation. J Immunol. 1999, 163 (9): 4663-4672.PubMed
58.
Zhou X, Jiang Y, Lu L, Ding Q, Jiao Z, Zhou Y, Xin L, Chou KY: MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation. Immunology. 2007, 122 (4): 476-485. 10.1111/j.1365-2567.2007.02674.x.CrossRefPubMedPubMedCentral
59.
Shankaranarayanan P, Chaitidis P, Kuhn H, Nigam S: Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem. 2001, 276 (46): 42753-42760. 10.1074/jbc.M102626200.CrossRefPubMed
60.
Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A: Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem. 2000, 275 (38): 29244-29256. 10.1074/jbc.M909467199.CrossRefPubMed
61.
Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM: The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2006, 20 (1): 14-34. 10.1210/me.2004-0488.CrossRefPubMed
62.
Noruzinia M, Coupier I, Pujol P: Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer. 2005, 104 (8): 1567-1574. 10.1002/cncr.21367.CrossRefPubMed
63.
Inoue T, Kamiyama J, Sakai T: Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem. 1999, 274 (45): 32309-32317. 10.1074/jbc.274.45.32309.CrossRefPubMed
64.
Lee TH, Chang HC, Chuang LY, Hung WC: Involvement of PKA and Sp1 in the induction of p27(Kip1) by tamoxifen. Biochem Pharmacol. 2003, 66 (3): 371-377. 10.1016/S0006-2952(03)00258-2.CrossRefPubMed
65.
Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, Corfe BM: Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer. 2010, 9: 275-10.1186/1476-4598-9-275.CrossRefPubMedPubMedCentral
66.
Deniaud E, Baguet J, Chalard R, Blanquier B, Brinza L, Meunier J, Michallet MC, Laugraud A, Ah-Soon C, Wierinckx A, et al: Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition. PLoS One. 2009, 4 (9): e7035-10.1371/journal.pone.0007035.CrossRefPubMedPubMedCentral
67.
Caldon CE, Sergio CM, Schutte J, Boersma MN, Sutherland RL, Carroll JS, Musgrove EA: Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol. 2009, 29 (17): 4623-4639. 10.1128/MCB.00269-09.CrossRefPubMedPubMedCentral
68.
Dai D, Wolf DM, Litman ES, White MJ, Leslie KK: Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002, 62 (3): 881-886.PubMed
69.
Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ: Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol. 2001, 194 (3): 327-333. 10.1002/path.910.CrossRefPubMed
70.
Said TK, Moraes RC, Singh U, Kittrell FS, Medina D: Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ. 2001, 12 (6): 285-295.PubMed
71.
Vorherr H: Pregnancy and lactation in relation to breast cancer risk. Semin Perinatol. 1979, 3 (3): 299-311.PubMed
72.
Medina D: Breast cancer: the protective effect of pregnancy. Clin Cancer Res. 2004, 10 (1 Pt 2): 380S-384S.CrossRefPubMed
73.
Narod SA: Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol. 8 (11): 669-676.
74.
Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TC, de Jong-van den Berg LT: Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol. 2005, 60 (6): 641-647. 10.1111/j.1365-2125.2005.02502.x.CrossRefPubMedPubMedCentral
75.
76.
Eden J: Progestins and breast cancer. Am J Obstet Gynecol. 2003, 188 (5): 1123-1131. 10.1067/mob.2003.201.CrossRefPubMed
77.
Sutherland RL, Watts CK, Musgrove EA: Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J Steroid Biochem Mol Biol. 1993, 47 (1–6): 99-106.CrossRefPubMed
78.
Darzynkiewicz Z, Gong J, Juan G, Ardelt B, Traganos F: Cytometry of cyclin proteins. Cytometry. 1996, 25 (1): 1-13. 10.1002/(SICI)1097-0320(19960901)25:1<1::AID-CYTO1>3.0.CO;2-N.CrossRefPubMed
79.
Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, Tokunaga H, Utsunomiya H, Yin P, Luo X, et al: Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 2010, 28 (1): 36-43. 10.1055/s-0029-1242991.CrossRefPubMedPubMedCentral
80.
Bedard PL, Freedman OC, Howell A, Clemons M: Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?. Breast Cancer Res Treat. 2008, 108 (3): 307-317. 10.1007/s10549-007-9606-8.CrossRefPubMed
81.
Milde-Langosch K, Loning T, Bamberger AM: Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat. 2003, 79 (2): 175-185. 10.1023/A:1023929504884.CrossRefPubMed
82.
Masciullo V, Susini T, Zamparelli A, Bovicelli A, Minimo C, Massi D, Taddei G, Maggiano N, De Iaco P, Ceccaroni M, et al: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res. 2003, 9 (14): 5332-5338.PubMed
83.
Tsuchiya A, Zhang GJ, Kanno M: Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol. 1999, 70 (4): 230-234. 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I.CrossRefPubMed
84.
Chu JS, Huang CS, Chang KJ: p27 expression as a prognostic factor of breast cancer in Taiwan. Cancer Lett. 1999, 141 (1–2): 123-130.CrossRefPubMed
85.
Chiarle R, Pagano M, Inghirami G: The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001, 3 (2): 91-94.CrossRefPubMed
86.
Zhang WJ, Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Xu SB, Zhang Y, Yuan J, Gerhard GS, et al: IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008, 42 (1): 39-47. 10.1016/j.cyto.2008.01.016.CrossRefPubMed
87.
Hartmann S, Martin-Subero JI, Gesk S, Husken J, Giefing M, Nagel I, Riemke J, Chott A, Klapper W, Parrens M, et al: Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by array-based comparative genomic hybridization. Haematologica. 2008, 93 (9): 1318-1326. 10.3324/haematol.12875.CrossRefPubMed
88.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455 (7216): 1061-1068.
89.
Wikman H, Nymark P, Vayrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M, et al: CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer. 2005, 42 (2): 193-199. 10.1002/gcc.20122.CrossRefPubMed
90.
de Marval PL M, Macias E, Conti CJ, Rodriguez-Puebla ML: Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene. 2004, 23 (10): 1863-1873. 10.1038/sj.onc.1207309.CrossRef
91.
Ali S, Buluwela L, Coombes RC: Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med. 2011, 62: 217-232. 10.1146/annurev-med-052209-100305.CrossRefPubMed
92.
Kremoser C, Albers M, Burris TP, Deuschle U, Koegl M: Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discov Today. 2007, 12 (19–20): 860-869.CrossRefPubMed
93.
Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W: Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005, 26 (3): 423-438. 10.1210/er.2005-0001.CrossRefPubMed
94.
Ahmad N, Kumar R: Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 2011, 300 (1): 1-9. 10.1016/j.canlet.2010.09.008.CrossRefPubMed
Metadata
Title
Integrity of the LXXLL motif in Stat6 is required for the inhibition of breast cancer cell growth and enhancement of differentiation in the context of progesterone
Authors
Min Wei
Qi He
Zhongyin Yang
Zhiwei Wang
Qing Zhang
Bingya Liu
Qinlong Gu
Liping Su
Yingyan Yu
Zhenggang Zhu
Guofeng Zhang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-10

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Case report

A late, solitary brain metastasis of epithelial ovarian carcinoma

Case report

Ectopic TSH-secreting pituitary tumor: a case report and review of prior cases

Research article

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

Erratum

Erratum to: Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma

Research article

Serum soluble ST2 is associated with ER-positive breast cancer

Research article

Predictors of recurrence free survival for patients with stage II and III colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits